Month: February 2026

GLEN ALLEN, Va., Feb. 04, 2026 (GLOBE NEWSWIRE) — Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today applauded the passage by Congress and signing into law by President Donald J. Trump of the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Bill, 2026. The final legislation incorporates Senate Report 119-55, which includes a significant Congressional directive to the U.S. Food and Drug Administration (FDA) and the National Institute on Drug Abuse (NIDA) to collaborate on the establishment of alternative clinical trial endpoints for medications treating substance use disorders, including Alcohol Use Disorder (AUD)....

DASSAULT AVIATION French corporation (société anonyme) with a share capital of 62,717,627.20 euros Headquarters: 78, quai Marcel Dassault 92210 SAINT-CLOUD 712 042 456 RCS Nanterre Information concerning the total number of voting rights and shares as per article L. 233-8 II of the French Commercial Code (Code de commerce) and article 223-16 of the General Regulations (Règlement Général) of the French Market Authority (Autorité des Marchés Financiers)DateTotal number of sharesTotal number of voting rights01/31/2026 78,397,034Theoretical voting rights: 130,565,778 Exercisable voting rights: 129,706,328AttachmentTotal number of shares and voting rights – 31 01 26

SINGAPORE, Feb. 04, 2026 (GLOBE NEWSWIRE) — Concorde International Group Ltd. (the “Company” or “CIGL”) (NASDAQ: CIGL), today announced that it has entered into an Agreement and Plan of Merger (the “Merger Agreement”) with YOOV Group Holding Limited (“YOOV”), a leading Artificial Intelligence-as-a-Service (AIaaS) platform specializing in digitalized business automation solutions. Amid accelerating digital transformation and rising global demand for intelligent service solutions, this strategic merger represents a landmark move to align two industry leaders with complementary strengths and shared growth ambitions. CIGL, a Nasdaq-listed company, has built a dominant regional footprint in security services, supported by proven operational execution, regulatory compliance, and a loyal client base spanning government agencies, multinational...

Beijing, Feb. 04, 2026 (GLOBE NEWSWIRE) — Tian Ruixiang Holdings Limited (“Tianruixiang” or the “Company”) (NASDAQ: TIRX), today announced the launch of its highly-anticipated Artificial Intelligence (“AI”) Strategic Initiative—a transformative, multi-billion-dollar ecosystem set to revolutionize insurance enterprises and leverage artificial intelligence to drive exponential growth, operational supremacy, and market dominance. This landmark move underscores TIRX’s aggressive pivot to become a global powerhouse in generative AI, predictive analytics, and autonomous systems, marking the most ambitious technological expansion in the Company’s history. “The era of incremental AI progress is over. Tianruixiang is here to ignite a revolution,” declared the CEO of Tian Ruixiang Holdings Limited. “With our TIRX AI Strategic Initiative,...

TORONTO, Feb. 04, 2026 (GLOBE NEWSWIRE) — Canadian Life Companies Split Corp. (“the Company”) is pleased to announce it has completed the overnight marketing of Preferred Shares (TSX: LFE.PR.B) and Class A Shares (TSX: LFE) of the Company. Total gross proceeds of the offering are expected to be approximately $60.1 million. The offering is being led by National Bank Financial Inc. The sales period of the overnight offering has now ended. The offering is expected to close on or about February 11, 2026 and is subject to certain closing conditions including approval by the TSX. The Preferred Shares were offered at a price of $10.45 per Preferred Share and the Class A Shares were offered at a price of $7.65 per Class A Share. The closing price on the TSX of each of the Preferred Shares and Class A Shares on February 3, 2026 was $10.55...

Geneva, Switzerland, Feb. 04, 2026 (GLOBE NEWSWIRE) — SEALSQ Corp (NASDAQ: LAES) (“SEALSQ” or “Company”), a company that focuses on developing and selling Semiconductors, PKI, and Post-Quantum technology ardware and software products, today announced that its CEO, Carlos Moreira, during his keynote at Tech&Fest (Progress Stage), presented the strategic vision and technical progress of a vertically integrated sovereign root-to-quantum security platform currently under development. Addressing the accelerating risks posed by quantum computing to embedded and mission-critical systems, Mr. Moreira emphasized the urgency of preparing for Q-Day, the moment when quantum capabilities render today’s cryptography obsolete. He outlined Europe’s need to act decisively to secure its digital, industrial, defense,...

MIAMI, Feb. 04, 2026 (GLOBE NEWSWIRE) — SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that members of its management team will participate in the following investor conferences in February: Guggenheim Securities Emerging Outlook: Biotech SummitDate: February 11, 2026Time: 10:30 a.m. ETFormat: Fireside ChatLocation: New York, NY Oppenheimer 36th Annual Healthcare Life Sciences ConferenceDate: February 25, 2026Time: 8:40 a.m. ETFormat: Fireside Chat Location: Virtual To access a live webcast of these events, as well as an archived recording, please visit the Investors & Media section of the Company’s website at www.sab.bio.   About SAB BIOSAB BIO is a clinical-stage...

LONDON and GAITHERSBURG, Md., Feb. 04, 2026 (GLOBE NEWSWIRE) — Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced that the Compensation Committee of the Company’s Board of Directors granted stock option awards to purchase an aggregate of 113,650 American Depositary Shares, representing an equal number of ordinary shares, to 22 employees pursuant to the Company’s 2025 Inducement Plan. The stock options were granted as an inducement material to the individual becoming an employee of Autolus in accordance with Nasdaq Listing Rule 5635(c)(4). The options have a grant date of January 26, 2026, and an exercise price of $1.46 per share, which is equal to the closing price of Autolus’...